Business Wire

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety

27.2.2023 23:33:00 EET | Business Wire | Press release

Share

In a keynote address at the Fifth Global Ministerial Summit on Patient Safety, Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), called for hospitals around the world to show greater transparency in reporting medical errors and preventable deaths. He also stressed the importance of aligned incentives, so providers are paid on quality of care rather than quantity and the adoption of Actionable Evidence-Based Practices addressing the known causes of harm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005765/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety (Photo: Business Wire)

“We need not just access to healthcare, it has to be safe, it has to be dignified,” said Kiani. “To get there, we have to create self-governing actions. If we can agree on the medical errors that can be prevented through evidence-based practices, those then can be tracked by every hospital. And they could report every year, every quarter, on their website publicly, the number of harms they have for each of those errors.”

Transparency, Kiani argued, is critical because publicly revealing data on preventable medical errors helps to accelerate the pace of change.

In countries where healthcare is at least partially subsidized by the government, Kiani suggested introducing major financial incentives for hospitals to be more transparent and active in patient safety by implementing evidence-based practices for preventing errors.

“In my country, half of the care is paid for by the Government. Medicare and Medicaid pays for more than half the care in every hospital,” he said. “So therefore, they could mandate that to get that reimbursement, they want transparency, and that they will tie their performance to the payment. So if hospitals have zero medical errors, zero preventable deaths, they don't have to do anything. But if someone is harmed, and those evidence-based practices were not in place, they should not get paid. This becomes a way that every board of directors of every hospital will expect their management to implement evidence-based practices.”

As an example of how this can work, Kiani cited his time on the board of directors of Children's Hospital of Orange County (CHOC), California. “When I began at CHOC, I was happy to see they were looking at quality,” he said. “They were looking at medical errors, but they were comparing themselves to their colleagues, and if they were lower in error rate than others, that was considered a job well done. And I challenged them that shouldn't the goal be zero? To their credit, they accepted the challenge, and they went one step further, they tied the bonuses of the faculty to zero. Something incredible occurred at the next meeting, we went from hoping for zero, to planning for zero.”

“I want you all to take action out of kindness!” concluded Joe Kiani.

The Global Ministerial Summit on Patient Safety is an annual event that brings together ministers, high-level representatives, and experts from around the world. This year’s summit was hosted by President Alain Berset and the distinguished speakers included; Tedros Adhanom Ghebreyesus, Director-General, World Health Organization; Professor Didier Pittet, Professor of Medicine at the University of Geneva; Dr. Anthony Staines, Patient Safety Program Director of Vaud Hospital Federation in Switzerland; Professor Dr. Phil Lauren Clark, Professor of Implementation Science in Health Care; and Professor Sir Liam Donaldson, WHO Patient Safety Envoy.

This year the Patient Safety Movement Foundation will hold its 10th Annual World Patient Safety, Science & Technology Summit on June 1st and 2nd in Newport Beach, California.

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP is available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye